However, the expressional changes in cancer cells contain the secondary changes induced by cancer driver signaling, such as KRAS [15], HIF [16] and p53 [17] signaling; thus, functional assessments, such as gene silencing and gene overexpression techniques, are applied to assess whether or not an aberrantly expressed molecule may be a cancer therapeutic target. This evidence concerns the gene TP53 and cancer.